Endothelium and hyperviscosity.
The role of viscosity, and of interindividual variations in this parameter, in the pathophysiology of cardiovascular disease remain incompletely understood. Any speculation regarding the possible impact of "hemorheological" therapies is therefore even more complex. In the last years, the debate regarding the relationship between increased viscosity and atherogenesis has been opened again. While the traditional view postulates that an increased blood viscosity has invariably a negative impact on tissue perfusion and therefore should be considered as a risk factor (when not as a true disease), a more recent hypothesis has been formulated based on the observation that small increases in viscosity actually have vasodilatory effects, potentially improving tissue perfusion.
Centro Siena-Toronto, University of Siena, Siena, Italy.
Sandro
S
Forconi
Philip
P
Wild
Thomas
T
Munzel
Tommaso
T
Gori
D000241:Adenosine / Q000627:therapeutic use; D001783:Blood Flow Velocity; D001794:Blood Pressure; D001809:Blood Viscosity; D002637:Chest Pain / Q000209:etiology / Q000503:physiopathology; D003327:Coronary Disease / Q000097:blood / Q000145:classification / Q000188:drug therapy / Q000503:physiopathology; D004176:Dipyridamole / Q000627:therapeutic use; D004730:Endothelium, Vascular / Q000503:physiopathology*; D006400:Hematocrit; D006801:Humans; D008955:Models, Cardiovascular; D015428:Myocardial Reperfusion Injury / Q000503:physiopathology; D018384:Oxidative Stress; D010974:Platelet Aggregation; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D012307:Risk Factors; D017131:Thrombectomy; D014664:Vasodilation; D014665:Vasodilator Agents / Q000627:therapeutic use
D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014665:Vasodilator Agents; D004176:Dipyridamole; D000241:Adenosine